Post-COVID-19 heart syndrome

Gąsecka, Aleksandra; Pruc, Michał; Kukula, Katarzyna; Gilis‐Malinowska, Natasza; Filipiak‬, Krzysztof J.; Jaguszewski, Miłosz; Szarpak, Łukasz

doi:10.5603/cj.a2021.0028

Cited by 33 publications

(36 citation statements)

References 9 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Myocardial injury detected by TTE and CMR among healthcare professionals, convalescents from non-severe COVID-19 has not been fully evaluated so far [4,5]. Left ventricular ejection fraction was decreased in 29% of cases, assessed by both TTE and CMR, and LV longitudinal myocardial function was also slightly decreased in 39% of the subjects.…”

Section: Resultsmentioning

confidence: 99%

Cardiac abnormalities detected by echocardiography and cardiac magnetic resonance in healthcare professionals recovered from non-severe COVID-19

et al. 2021

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Cardiac abnormalities detected by echocardiography and cardiac magnetic resonance in healthcare professionals recovered from non-severe COVID-19

et al. 2021

View full text Add to dashboard Cite

“…The manifestations of COVID-19 are not specific. The most common symptoms are cough, fever, tiredness and loss of smell and taste, but production of sputum, sore throat, headache, nausea vomiting and diarrhea may also indicate infection [ 1 , 5 , 6 , 7 ]. Transmissibility peaks just before their onset.…”

Section: Introductionmentioning

confidence: 99%

Effect of Coronary Artery Disease on COVID-19—Prognosis and Risk Assessment: A Systematic Review and Meta-Analysis

Szarpak

Mierzejewska

Jurek

et al. 2022

Biology

Self Cite

View full text Add to dashboard Cite

Coronary artery disease (CAD) is the leading cause of death worldwide. Patients with pre-existing CAD were shown to have a more severe course of COVID-19, but this association has not been clarified. We performed a meta-analysis to determine the association between CAD and COVID-19 outcomes. We searched Scopus, Medline (PubMed), Web of Science, Embase, and Cochrane databases up to November 2nd, 2021. There were 62 studies with a total population of 49,286 patients included in the meta-analysis. CAD occurrence in survivor vs. non-survivor groups varied and amounted to 9.2% vs. 22.9%, respectively (OR = 0.33; 95%CI: 0.29 to 0.39; I2 = 70%; p < 0.001). CAD was also associated with increased severity of COVID-19 disease and was (10.8% vs. 5.6%, respectively, for severe vs. non-severe groups (OR = 2.28; 95%CI: 1.59 to 3.27; I2 = 72%; p < 0.001). The role of history of CAD in mortality and severe condition in COVID-19 presents itself as prominent—although a risk of bias in retrospective trials needs to be assessed, in case of our meta-analysis the statistically significant results when it comes to higher mortality among patients with CAD compared to non-CAD patients, a more severe condition observed in patients with CAD, and a visibly more frequent admission to intensive care unit in patients with CAD, it seems that an incidence of cardiovascular events plays a role in COVID-19 prognosis.

show abstract

“…Persistent cardiac involvement and ongoing myocarditis were observed in COVID-19 convalescents (78% and 60%, respectively) in cardiac magnetic resonance even 3 months after the acute phase of the disease. Moreover, imaging changes have been described in people who had no symptoms of COVID-19, raising the possibility that post-COVID heart syndrome may be the first sign of a past infection [103]. Hence, whereas the short-term complications of acute COVID-19 are relatively clear, the knowledge regarding long-term effects, especially on the progression of ASCVD, requires further investigation.…”

Section: Severe Acute Respiratory Syndrome Coronavirus-2 (Sars-cov-2)mentioning

confidence: 99%

Infections as Novel Risk Factors of Atherosclerotic Cardiovascular Diseases: Pathophysiological Links and Therapeutic Implications

Szwed

Zawadka

Eyileten

et al. 2021

JCM

Self Cite

View full text Add to dashboard Cite

Atherosclerotic cardiovascular diseases (ASCVD) are the major cause of mortality worldwide. Despite the continuous progress in ASCVD therapy, the residual risk persists beyond the management of traditional risk factors. Several infections including Helicobacter pylori infection, periodontal disease, and viral infections are associated with the increased risk of ASCVD, both directly by damage to the heart muscle and vasculature, and indirectly by triggering a systemic proinflammatory state. Hence, beyond the optimal management of the traditional ASCVD risk factors, infections should be considered as an important non-classical risk factor to enable early diagnosis and appropriate treatment. Here, we summarized the currently available evidence regarding the role of inflammation in ASCVD and the association between the particular infections and pathogens (Helicobacter pylori, periodontal disease, pneumonia, Cytomegalovirus, Human immunodeficiency virus, Herpes simplex virus, and severe acute respiratory syndrome coronavirus 2) on the development and progression of ASCVD. We also speculated about the potential therapeutic implications of the anti-inflammatory and anti-infective drugs on ASCVD outcomes, including drugs routinely administered in patients with ASCVD (statins, P2Y12 receptor inhibitors, and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers) and novel strategies aiming at residual risk reduction (colchicine, anti-cytokine drugs, and methotrexate). Considering the emerging association between infections and ASCVD, it is crucial to determine the possible advantages of infection prevention and treatment in patients with ASCVD.

show abstract

Post-COVID-19 heart syndrome

Cited by 33 publications

References 9 publications

Cardiac abnormalities detected by echocardiography and cardiac magnetic resonance in healthcare professionals recovered from non-severe COVID-19

Cardiac abnormalities detected by echocardiography and cardiac magnetic resonance in healthcare professionals recovered from non-severe COVID-19

Effect of Coronary Artery Disease on COVID-19—Prognosis and Risk Assessment: A Systematic Review and Meta-Analysis

Infections as Novel Risk Factors of Atherosclerotic Cardiovascular Diseases: Pathophysiological Links and Therapeutic Implications

Contact Info

Product

Resources

About